Effects of Chronic Use of Doxazosin in Men With Benign Prostatic Hyperplasia

• Status: Completed
• Trial end date: 2010-03-01
• Target enrollment: 0
• Participant gender: Male

Summary

In this study, we investigate the changes of the expression of alpha adrenergic receptor in the prostate tissue during 2-yr medication period in the man with benign prostatic hyperplasia. And we also evaluate the efficacy and safety of 24 mo-treatment with doxazosin (4mg, 8mg)

• Phase: N/A
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Samsung Medical Center
• Treatments: Adrenergic Agents; Doxazosin

Criteria

Inclusion Criteria:

• 50 yrs or greater

• International prostatic symptom score >= 8

• Maximal flow rate < 15mL/sec

• baseline PSA 2.5-10 ng/mL

• Pathologically proven BPH

• No medication history for BPH

• Able to give fully informed consent

Exclusion Criteria:

• Previous use of alpha-blocker, 5-alpha reductase inhibitor

• Previous surgery for BPH

• Urologic cancer history

• Urethral stricture

• baseline PSA > 10ng/mL

• BP < 90/70 mmHg

• Orthotopic hypotension with syncope

• Serum Cr > 2.0 mg/dl, alanine aminotransferase > 1.5 times of normal limit

• Bacterial prostatitis within 1 year

• Urinary tract infection(UTI) more than 2 times within 1 year

• Active UTI or prostate biopsy within 1 month

• Unable to void

• Ped use because of incontinence

• Hypersensitivity to alpha-blocker that include quinazoline

• Unstable angina, Myocardial infarction, or cerebrovascular accident within 6 months

• Neurogenic bladder dysfunction (ex. multiple sclerosis, Parkinson's disease, Spinal injury etc.)

• Psychiatric problem

• Alcohol abuse or other drug abuse history

• Severe comorbidities unable to perform long-term trial

• seems not to be appropriate to this study because of any other reasons